Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

MAP Pharmaceuticals Announces Termination Of Pediatric Asthma Collaboration
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company"s Unit Dose Budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement now revert to the company. MAP Pharmaceuticals plans to suspend development of UDB, which did not meet primary endpoints in a Phase 3 trial in children 12-months to eight years of age with mild asthma.
pharmacy online
E-health Enables More Personalized Medicine; Group Fights For Digital Patient Rights
Tonia Odom, a 35-year-old patient with rheumatoid arthritis, a sick father and a young son, each of whom has multiple health problems, has found some relief to the problems of managing her families" array of illnesses in at a Duke University clinic that"s a model of the "medical home" approach to medicine, the New York Times reports. "As President Obama and Congress try to create a national system that provides better care for more people at lower cost, you are likely to hear a lot more about this idea. The term, coined by the American Academy of Pediatrics in 1967, is admittedly confusing. It does not mean a return to house calls. Nor need it apply only to people with complex health problems like those of the Odom family."
News of the day
Sunwin International Increases Availability Of Two Veterinary Medicines To Combat Swine Flu Virus In China
Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), a leader in the production and distribution of Chinese herbs, veterinary medicines and one of the world"s leading producers of all natural, zero calorie Stevia in China, announced today that the company has increased the availability of two veterinary medicines, Huangqiduotang vaccine and Jinfang Detoxification Powder to treat swine flu that has recently spread in North America and other parts of the world. These products, currently used for controlling various types of influenza in China, have demonstrated effectiveness in controlling swine flu outbreaks among livestock.
Sexual Health

Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study

UroToday.com - Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors. A missense mutation in the coding region for endostatin has been described, but the polymorphism affects protein conformation rather than protein expression. Cellular assays suggested that the result is impaired endostatin binding to laminin, a basement membrane protein. In an online article in the International Journal of Cancer, Dr. Lorelei Mucci and colleagues present data from the Physicians" Health Study examining the D104N endostatin polymorphism in relation to prostate cancer risk and survival. The Physicians" Health Study was a randomized trial of aspirin and beta-carotene supplementation among 22,071 physicians ages 40-84 that was initiated in 1982. A total of 14,916 participants had samples available for this nested case-control study. The analysis identified 544 incident prostate cancer cases and 678 controls for polymorphism genotyping. Among the control men, 84.2% were wildtype homozygous (DD), 14.5% were heterozygous (DN), and 1.3% were homozygous carriers of the rare allele (NN). Carriage of the polymorphic N allele was not associated with risk of total prostate cancer risk. There was no evidence that the endostatin D104N polymorphism was associated with prostate cancers diagnosed at a younger or older age. There was also no association between carriage of the N allele and development of lethal prostate cancer. Participants whose prostate cancer contained the polymorphic allele were less likely to be overweight or obese (26%) compared to men with the DD genotype (47.8%). This large study observed no overall association between the D104N endostatin polymorphism and prostate cancer risk or prognosis. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW Int J Cancer. 2009 Mar 11. (Epub ahead of print) 10.1002/ijc.24423 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009